(RTTNews) - MediciNova, Inc. (MNOV) shares are rising on Wednesday morning trade after the biopharma company announced the intranasal SARS CoV-2 vaccine prototype for COVID-19.
The company confirmed a high IgA antibody titer against S1 Ag in the nasal lavage fluid from mice given intranasal BC-PIV SARS-CoV-2 vaccine.
Currently, the shares are at $6.16, up 11.37 percent from its previous close of $5.54 on a volume of 11,322,469. The stock has traded in a range of $2.79 to $13.25 on average volume of 1,668,170.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
